MedTrace Logo

Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

NCT05877859 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2026-05-07

No results posted yet for this study

Summary

This research study is a prospective, single arm, pilot study, designed to evaluate the correlation between the immune and clinical responses of subjects with untreated Stage II-III triple negative breast cancer (TNBC) undergoing standard of care neoadjuvant chemo- immunotherapy.

Conditions

  • Breast Cancer Triple Negative
  • Breast Cancer Stage II
  • Breast Cancer Stage III
  • Breast Cancer Invasive

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Emory University

    lead OTHER

Principal Investigators

  • Ruth Sacks, MD · Emory University Hospital/Winship Cancer Institute

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-30
Primary Completion
2027-02-20
Completion
2028-02-20

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05877859 on ClinicalTrials.gov